Tumor Immunology Flashcards

1
Q

2 key cytokines that down-regulate T cell responses

A

TGF-beta and IL-10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Ligand that provides activatory signals to NK cells

A

MIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

MIC ligand provides activatory signals to NK cells through this

A

NKG2D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MIC ligand activates these cells

A

NK cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pembrolizumab, Nivolumab, and Cemiplimab are monoclonal antibodies against this

A

PD-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Atezolizumab, Avelumab, and Durvalumab are monoclonal antibodies against this

A

PD-L1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

PD-L1/PD-1 binding has this effect

A

Inhibits T cell killing of tumor cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Blocking PD-L1/PD-1 binding has this effect

A

Allows T cell killing of tumor cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Antigen for Gemtuzumab

A

CD33

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

CD33 is a marker for these

A

Immature myeloid cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Gemtuzumab is used for this disease

A

Acute myelogenous leukemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ibritumomab is used for this disease

A

Non-Hodgkin’s lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Tositumomab is used for this disease

A

Non-Hodgkin’s Lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Monoclonal antibody against CD33 for treatment of acute myelogenous leukemia

A

Gemtuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

2 monoclonal antibodies that target CD20 in the treatment of Non-Hodgkin’s Lymphoma

A

Ibritumomab and Tositumomab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Antigen target of Ibritumomab

A

CD20

17
Q

Antigen target of Tositumomab

A

CD20

18
Q

Monoclonal antibody linked directly to the cytotoxic antibiotic dervided ozogamicin

A

Gemtuzumab

19
Q

Gemtuzumab is linked directly to this

A

Cytotoxic antibiotic derived Ozogamicin

20
Q

Monoclonal antibody linked through the chelator tiuxetan to indium-111 for imaging and yttrium-90 for treatment

A

Ibritumomab

21
Q

Ibritumomab is linked through this to indium-111 for imaging and yttrium-90 for treatment

A

The chelator Tiuxetan

22
Q

Ibritumomab is linked through the chelator tiuextan to this for imaging

A

Indium-111

23
Q

Ibritumomab is linked through the chelator tiuextan to this for treatment

A

Yttrium-90

24
Q

Monoclonal antibody that is linked to iodine-131

A

Tositumomab

25
Q

Tositumomab is linked to this

A

Iodine-131

26
Q

Vaccination using these proteins from dying tumor cells has demonstrated a potential for strong anti-tumor responses

A

Heat shock

27
Q

T cell that recognizes antigen like a B cell (recognize protein)

A

Chimeric antigen receptor (CAR) T cells

28
Q

How are CAR T cells different from regular TCRs?

A

Recognize proteins (antibody-like); recognize antigen directly
Normal TCRs recognize peptide:MHC

29
Q

Fusion protein of antigen-binding region from heavy and light chains connected by a 10-25 amino acid linker

A

Single-chain variable fragment (scFv)